Last reviewed · How we verify
Tiotropium + formoterol/beclometasone
This combination drug provides long-acting bronchodilation via tiotropium (anticholinergic) and formoterol (beta-2 agonist), plus anti-inflammatory action via beclometasone (inhaled corticosteroid) for maintenance treatment of chronic obstructive pulmonary disease and asthma.
This combination drug provides long-acting bronchodilation via tiotropium (anticholinergic) and formoterol (beta-2 agonist), plus anti-inflammatory action via beclometasone (inhaled corticosteroid) for maintenance treatment of chronic obstructive pulmonary disease and asthma. Used for Chronic obstructive pulmonary disease (COPD) maintenance treatment, Asthma maintenance treatment.
At a glance
| Generic name | Tiotropium + formoterol/beclometasone |
|---|---|
| Also known as | Inuvair (B10356) |
| Sponsor | KU Leuven |
| Drug class | Long-acting anticholinergic/long-acting beta-2 agonist/inhaled corticosteroid combination |
| Target | Muscarinic M3 receptor, beta-2 adrenergic receptor, glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Tiotropium is a long-acting muscarinic antagonist that blocks acetylcholine-mediated bronchoconstriction. Formoterol is a long-acting beta-2 adrenergic agonist that promotes bronchial smooth muscle relaxation. Beclometasone is an inhaled corticosteroid that reduces airway inflammation. Together, these three agents provide sustained bronchodilation and anti-inflammatory effects in a single inhaled formulation.
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance treatment
- Asthma maintenance treatment
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Hoarseness
- Muscle cramps
Key clinical trials
- Asthma Research in Children and Adolescents
- Acupuncture for Persistent Dyspnea Despite Medical Treatment in COPD (NA)
- Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints
- Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease (PHASE4)
- Non Inferiority of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) Versus Combination of Fluticasone Furoate (FlF)/Vilanterol (VI) + Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
- Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary Disease (PHASE3)
- Personalized Treatment Algorithms for Difficult-to-treat Asthma (PHASE2)
- TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tiotropium + formoterol/beclometasone CI brief — competitive landscape report
- Tiotropium + formoterol/beclometasone updates RSS · CI watch RSS
- KU Leuven portfolio CI